All News

Gene Editing

Cell and Gene Therapies News Round-Up: November 1
1 November 2024
Cell and Gene Therapies News Round-Up: November 1
This week, Phacilitate's cell and
European Commission Grants Approval for CASGEVY™ for Treatment of Sickle Cell Disease and Beta-Thalassemia
13 February 2024
European Commission Grants Approval for CASGEVY™ for Treatment of Sickle Cell Disease and Beta-Thalassemia
The European Commission has granted
Advanced Therapies Week 2024 Opening Plenary: Striving for a Future of Development Whilst Celebrating the Past
8 February 2024
Advanced Therapies Week 2024 Opening Plenary: Striving for a Future of Development Whilst Celebrating the Past
Advanced Therapies Week 2024's Opening
Advanced Therapies Week 2024: Navigating Innovation, Patient-Centricity, and the Regulatory Landscape in Cell and Gene Therapy
7 February 2024
Advanced Therapies Week 2024: Navigating Innovation, Patient-Centricity, and the Regulatory Landscape in Cell and Gene Therapy
POPULAR NEWS ITEMS
Image
26 November 2024

ATW Speaker Patrick M Gailliot Previews Event and Discusses His Role in Autologous Cell and Gene Therapies

Image
19 November 2024

Texas Cell and Gene Manufacturing Landscape

Image
12 November 2024

Full Agenda Released for Advanced Therapies Week 2025 in Dallas

Tech Demo: GMP Cyrovial Filling Platform, from 3P Innovation
12 January 2024
Tech Demo: GMP Cyrovial Filling Platform, from 3P Innovation
David Johnson, Sales and Marketing
IN8bio’s INB-200 Demonstrates Remarkable Progression-Free Survival in Newly Diagnosed Glioblastoma Patients
22 November 2023
IN8bio’s INB-200 Demonstrates Remarkable Progression-Free Survival in Newly Diagnosed Glioblastoma Patients
IN8bio, Inc. has presented compelling
First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
16 November 2023
First CRISPR/Cas9 Gene-Edited Therapy Authorized by the UK MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
The First regulatory authorization of
Verve Therapeutics’ VERVE-101 Demonstrates Breakthrough in vivo Base Editing for Familial Hypercholesterolemia
15 November 2023
Verve Therapeutics’ VERVE-101 Demonstrates Breakthrough in vivo Base Editing for Familial Hypercholesterolemia
Verve Therapeutics shows promising reductions
Load more News
RECOMENDED TOPICS
Allogeneic
Autologous
CAR-X
Cell Therapy
Cell-Based IO
Gene Editing
Gene Therapy
NKx
Stem Cells
Tissue Engineering
Viral/Non-Viral Vectors
POPULAR NEWS ITEMS
Image

ATW Speaker Patrick M Gailliot Previews Event and Discusses His Role in Autologous Cell and Gene Therapies

Image

Texas Cell and Gene Manufacturing Landscape

Image

Full Agenda Released for Advanced Therapies Week 2025 in Dallas